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Non-radioactive cellular cytotoxicity assay
Terbium
Terpyridine
A B S T R A C T
The adoptive transfer of immune effector cells, such as CD8+ killer αβ T cells, γδ T cells, NK (natural killer) cells,
and genetically–modified T cells, has been receiving increasing attention. It is essential to determine cellular
cytotoxicity so as to monitor the function and quality of ex vivo–expanded immune effector cells before infusion.
The most common method is the [51Cr]–sodium chromate release assay. It is, however, preferable to avoid the
use of radioactive materials in clinical laboratories. In order to establish a non-radioactive alternative to the
standard radioactive assay, we previously synthesized a chelate–forming prodrug (BM-HT) and demonstrated
that a combination of BM-HT and europium (Eu3+) was useful to determine NK cell–mediated cytotoxicity. In
the present study, we examined whether or not this improved assay system could be used to determine the
cellular cytotoxicity exhibited by Vγ2Vδ2+ γδ T cells. In addition, we compared Eu3+ and terbium (Tb3+) in the
measurement of cellular cytotoxicity. Our assay system using BM-HT could be used successfully for the analysis
of both γδ T cell receptor (TCR)– and CD16–mediated cytotoxicity. When the intensity of fluorescence was
compared between Eu3+ and Tb3+, Tb3+ chelate was more sensitive than Eu3+ chelate, suggesting that the
detection system using Tb3+ is superior to Eu3+ when tumor cells are not efficiently labeled with BM-HT. The
method established herein is expected to promote the development of novel adoptive cell therapies for cancer.
1. Introduction
Cancer immunotherapy has received significant attention since the
success of immune checkpoint inhibitors and chimeric antigen receptor
(CAR)–T cells (Leach et al., 1996; Iwai et al., 2002; Couzin-Frankel,
2013; June and Sadelain, 2018). For the adoptive transfer of immune
effector cells, it is essential to determine cellular cytotoxicity in clinical
laboratories. The most common method to monitor the cytotoxicity of
ex vivo–expanded immune effector cells is the [51Cr]‑sodium chroma-
te–release assay (Brunner et al., 1968). In this assay system, radi-
o–labeled target cells are challenged by immune effector cells, and the
amount of intracellular and extracellular [51Cr]‑sodium chromate is
determined through a γ-counter at the end of the assay. This radioactive
assay system is reliable and reproducible, and is therefore the gold
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standard for cell–medicated cytotoxicity measurement. The dis-
advantages of this method, however, include the handling and disposal
of radioactive materials that are strictly regulated in clinical labora-
tories. A number of non-radioactive methods have been developed,
including assays based on the detection of intracellular enzymes, such
as alkaline phosphatase (Szekeres et al., 1981) and lactate dehy-
drogenase (Sepp et al., 1996), the release of fluorescent probes (Bruning
et al., 1980), and single cell analysis by flow cytometry (Packard and
Komoriya, 2008).
One of the most promising approaches for an alternative to the
radioactive cytotoxicity assay is time–resolved fluorometry (TRF)
(Kolber et al., 1988; Volgmann et al., 1989; Maley and Simon, 1990;
Blomberg and Ulfstedt, 1993; Pacifici et al., 1993; Lövgren and
Blomberg, 1994; Blomberg et al., 1996; von Zons et al., 1997; Wu and
Zhang, 2002; Zaritskaya et al., 2010). When the target tumor cells are
treated with a prodrug of a chelate–forming compound, the probe
prodrug permeates the cell membrane, where the compound is hydro-
lyzed by intracellular esterases to give a chelate–forming compound.
The nascent compound is negatively charged and no longer permeates
the cell membrane freely. Upon encountering the labeled target cells,
immune effector cells such as natural killer (NK) cells and Vγ2Vδ2+ γδ
T cells secrete perforin and perforate the target cell membrane. The
immune effector cells then deliver granzyme B through the membrane
holes into the target cells. Granzyme B is a pro-apoptotic protein that
causes the target cells to undergo apoptosis. During apoptosis, the
chelate–forming probe is released from the disrupted membrane into
the culture media. Upon the addition of europium (Eu3+) to the culture
media, a probe/Eu3+ chelate is formed. When the chelate solution is
pulsed with excitation light of 340 nm, the probe/Eu3+ chelate emits
specific fluorescence. As the decay time of the fluorescence derived
from the chelate is longer than that from the fluorescent ingredients
present in the media, the long–lived fluorescence can be measured
using a TRF multiplate reader.
Since the efficiency of cell labeling was relatively low and the
spontaneous release rate was high when previously developed
TRF–probes were employed, we recently synthesized bis(butyrylox-
ymethyl) 4′-hydroxymethyl-2,2′:6′,2″-terpyridine-6,6″-dicarboxylate
(BM-HT), a prodrug of 4′-hydroxymethyl-2,2′:6′,2″-terpyridine-6,6″-
dicarboxylate (HT) (Sakai et al., 2017), and demonstrated that a com-
bination of BM-HT and Eu3+ could be used for the determination of NK
cell–mediated cytotoxicity (Senju et al., 2018). In the present study, we
examined whether the newly improved assay can be used for the de-
termination of Vγ2Vδ2+ γδ T cell–mediated cellular cytotoxicity and
further improved the assay method using terbium (Tb3+).
2. Materials and methods
2.1. Derivation of human Vγ2Vδ2+ γδ T cells
Heparinized peripheral blood samples were obtained from ten
healthy adult volunteers (HD01-HD10) after approval of the institu-
tional review board of Nagasaki University Hospital and with written
informed consent. All methods were performed in accordance with the
guidelines and regulations of Nagasaki University Hospital. The blood
samples (10mL) were diluted with 10mL of Dulbecco's phosphate–-
buffered saline (−) (PBS, Nissui Pharmaceutical Co., Ltd. Taito-ku,
Tokyo, Japan) and loaded on Ficoll-Paque™ PLUS (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden). After gradient centrifugation at 600 x g
for 30min at ambient temperature, peripheral blood mononuclear cells
(PBMCs) fraction was collected. The cells were washed two times with
35mL of PBS (−) and resuspended in 7mL of Yssel's medium con-
taining human AB serum (Cosmo Bio Co., Ltd., Koto-ku, Tokyo, Japan).
Of the cell suspension, 1mL was used for flow cytometric analysis. To
the rest of the cell suspension (6mL) were added 6 μL of tetrakis-pi-
valoyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate
(PTA, 1mM dimethylsulfoxide solution) (Techno Suzuta Co., Ltd.,
Heiwa-Machi, Nagasaki, Japan) to give a final concentration of 1 μM
and the plate was incubated at 37 °C with 5% CO2 for 24 h. The culture
medium was replaced with Yssel's medium plus 100 U/mL of IL-2
(Shionogi Pharmaceutical Co., Ltd., Chuo-ku, Osaka, Japan) from day 1
through day 5 and with RPMI1640 medium (Merck & Co., Inc.,
Kenilworth, NJ) supplemented with 10% fetal calf serum (FCS) (Merck
& Co., Inc.), 10−5 M 2-mercaptoethanol (Wako Pure Chemical
Industries, Ltd., Chuo-ku, Osaka, Japan), 100 U/mL of penicillin (Meiji
Seika Pharma Co., Ltd., Chuo-ku, Tokyo, Japan), 100 μg/mL of strep-
tomycin (Meiji Seika Pharma Co., Ltd.), and 100 U/mL IL-2 from day 6
through day 10. On day 11, the cells were harvested and analyzed for
the expression of cell surface markers and the immune effector func-
tions.
2.2. Tumor cell lines
K562 (erythrocytoma), U937 (monocytic leukemia), P31/FUJ
(monocytic leukemia), and RAMOS-RAI (Burkitt's lymphoma) were
obtained from the National Institutes of Biomedical Innovation, Health
and Nutrition JCRB Cell Bank (Ibaraki, Osaka, Japan). KG-1 (monocytic
cell line) and 786-0 (renal cell carcinoma) were purchased from
American Type Culture Collection (Manassas, VA) and C1R (B cell
lymphoma) was obtained from RIKEN BioResource Center (Tsukuba,
Ibaraki, Japan). UOK111 (renal cell carcinoma) and UOK121 (renal cell
carcinoma) were kind gifts from Dr. Hirohito Kobayashi (Tokyo
Women's Medical University, Shinjuku-Ku, Tokyo, Japan).
2.3. Flow cytometric analysis
PBMCs or PTA–expanded cells were plated out at 2×105 cells/
50 μL in a 96-well plate (Corning Inc.). The cells were incubated with
3 μL of mAbs, including fluorescein isothiocyanate (FITC)–conjugated T
cell receptor (TCR) Vδ2 mAb (BD Biosciences, San Diego, CA) and
phycoerythrin (PE)–conjugated anti-cluster of differentiation 3 (CD3)
mAb and anti-CD16 mAb (BD Biosciences) on ice for 15min. After
being washed three times with 200 μL of PBS, the cells were re-
suspended in 400 μL of PBS and analyzed using a FACSCalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ). The cell population
was analyzed using FlowJo ver. 10. (FlowJo LLC, Ashland, Oregon).
2.4. Determination of spontaneous release rate of chelate-forming ligand
Renal cell carcinoma cell lines 786-0, UOK111, and UOK121 were
grown in 30mL of complete RPMI1640 medium in 75 cm2 culture flasks
at 37 °C with 5% CO2 for 2 days. The culture medium was removed and
the cells were washed once with 10mL of PBS (−). Then, the cells were
treated with 0.25% trypsin/0.5 mM disodium ethylenediaminete-
traacetic acid (EDTA, Merck & Co., Inc.) at 37 °C with 5% CO2 for 5min,
to which were added 10mL of complete PRMI1640 medium. The cells
were washed twice with the medium and resuspended in the medium at
a cell concentration of 1× 106 cells/mL. For labeling cells, 2.5 μL of
10mM bis(butyryloxymethyl) 4′-hydroxymethyl-2,2′:6′,2″-terpyridine-
6,6″-dicarboxylate (BM-HT), a non-radioactive chelate-forming proli-
gand (Techno Suzuta Co., Ltd., Heiwa-Machi, Nagasaki, Japan), was
added to the cell suspension to give a final concentration of 25 μM.
After incubation for 15min at 37 °C with 5% CO2, the cells were washed
three times with 5mL of complete RPMI1640 medium and resuspended
in 20mL of the medium to give a cell concentration of 5×104 cells/
mL. The cell suspensions (100 μL each) were placed in 6 wells of a 96-
well round bottom plate (Merck & Co., Inc.), to three wells of which
were added 100 μL of complete RPMI1640 medium for the determi-
nation of spontaneous release and to the remaining three wells of which
were added 90 μL of complete RPMI1640 medium for the determination
of maximum release. The plate was centrifuged at 500 rpm at room
temperature for 2min in an AX-521 low speed centrifuge (Tomy Seiko
Co., Ltd.) and incubated at 37 °C with 5% CO2 for 30min. Then, 10 μL
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of 0.125% digitonin (Wako Pure Chemical Industries Ltd.) in 19% di-
methylsulfoxide (Wako Pure Chemical Industries Ltd.) were added to
three wells for the determination of maximum release. The plates were
incubated at 37 °C with 5% CO2 for 30 more min and centrifuged at 600
x g for 2min at 4 °C. The supernatants (25 μL each) were removed into
wells of 96-well round bottom plates (Merck & Co., Inc.) containing
250 μL each of Tb3+ or Eu3+ solution (50 μMTb 3+ or Eu3+ (Merck &
Co., Inc.) in 0.3 M sodium acetate buffer, pH 4.0 (Wako Pure Chemical
Industries Ltd.)). The samples were mixed well and 200 μL each of them
were removed into a 96-well optical bottom plate with polymer base
(Thermo Fisher Scientific Inc., Waltham, MA). Then, TRF was de-
termined through a PHERAstar FS multiplate reader (BMG Labtech Ltd.,
Allmendgruen, Ortenberg, Germany). All experiments were performed
in triplicate. The maximum release was calculated as [maximum release
(counts) – background (counts)] and the spontaneous release as
[spontaneous release (counts) – background (counts)]. Then, the
spontaneous release rate (%) was calculated as [(100 x spontaneous
release)/maximum release].
2.5. Cellular cytotoxicity assay
Tumor cells were grown in 30mL of complete RPMI1640 medium in
75 cm2 culture flasks at 37 °C with 5% CO2 for 2 days and resuspended
in the medium at a cell concentration of 1× 106 cells/mL. To 1mL of
the tumor cell suspension was added 2.5 μL of BM-HT and the tumor
cells/BM-HT were incubated for 15min at 37 °C with 5% CO2. After
being washed three times with 5mL complete RPMI1640 medium, the
labeled tumor cells were washed three times with the medium and
resuspended in 20mL of the medium to give a cell concentration of
5× 105 cells/mL. The cell suspension was plated out in a round bottom
96-well plate (5×104 cells/100 μL) (Corning Inc.) and challenged by
100 μL of Vγ2Vδ2+ γδ T cells at effector to target ratios of 0, 0.625,
1.25, 2.5, 5, 10, 20 and 40: 1 for 60min at 37 °C with 5% CO2. After
being centrifuged at 600 x g for 2min at room temperature, the su-
pernatants (25 μL each) were removed to a new round bottom 96-well
plate containing 250 μL of Tb3+ or Eu3+ solution, from which 200 μL
samples were transferred to a 96-well optical plate (Thermo Fisher
Scientific Inc.). TRF was measured through a PHERAstar FS multiplate
reader (BMG Labtech Ltd.). All experiments were performed in tripli-
cate. Specific lysis (%) was calculated as 100 x [experimental release
(counts) – spontaneous release (counts)] / [maximum release (counts) –
spontaneous release (counts)] and spontaneous release (%) was calcu-
lated as100 x [spontaneous release (counts) – background (counts)] /
[maximum release (counts) – background (counts)].
2.6. ADCC assay
To determine the antigen–dependent cellular cytotoxicity (ADCC),
Fig. 1. Comparison of terbium and europium in the measurement of spontaneous release rates of HT from tumor cells. The effect of Tb3+ and Eu3+ on the
spontaneous release rate of HT from human renal cell carcinoma cell lines 786-0, UOK111, and UOK121 were determined. Data show mean ± SD and are re-
presentative of five independent experiments.
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RAMOS-RAI Burkitt's lymphoma cells were pre–incubated with anti-
CD20 mAb (Rituximab, Zenyaku Kogyo Co., Ltd., Bunkyo, Tokyo,
Japan) at concentrations of 0, 0.5 or 2 μg/mL for 15min at 37 °C with
5% CO2. The opsonized tumor cells were then challenged by CD16-
positive and negative Vγ2Vδ2+ γδ T cells. ADCC was determined as
described in the “Cellular cytotoxicity assay” section. All experiments
were performed in triplicate.
2.7. Average and standard deviation
Average and standard deviation were calculated using CA-Cricket
Graph III (version 1.5.3).
3. Results
3.1. Comparison of Tb3+ and Eu3+ in tumor cell labeling
We previously synthesized bis(butyryloxymethyl) 4’hydroxymethyl-
2,2′:6′,2″-terpyridine-6,6″-dicarboxylate (BM-HT), a prodrug of 4′-hy-
droxymethyl2,2′:6′,2″-terpyridine-6,6″-dicarboxylate (HT), and im-
proved a non-radioactive cellular cytotoxicity assay (Sakai et al., 2017).
We initially used Eu3+, one of the lantanoid metals, to form a fluor-
escent chelate with HT, because the Stokes shift (a difference between
positions of the band maxima of the absorption and emission spectra) of
the HT/Eu3+ chelate is relatively large. Since Tb3+, another lantanoid
metal, is known to form a complex with terpyridine dicarboxylate de-
rivatives, we first compared the emission fluorescence properties
Fig. 2. Comparison of terbium and europium in the determination of Vγ2Vδ2+ γδ T cell-mediated cytotoxicity. The effect of Tb3+ and Eu3+ on the specific lysis by
Vγ2Vδ2+ γδ T cells (HD01, HD02, and HD03) of HT-labeled and PTA-sensitized 786-0 cells were determined (○, 0 nM PTA;●, 200 nM PTA). Data show mean ± SD
and are representative of three independent experiments.
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between HT/Tb3+ and HT/Eu3+.
When the emission spectra of HT/Tb3+ and HT/Eu3+ after excita-
tion at 340 nm were compared at the same molar concentration
(0.5 μM), specific fluorescence was observed at 545 nm for HT/Tb3+
and 615 nm for HT/Eu3+, with the maximum fluorescence values being
769.481 for HT/Tb3+ and 52.161 for HT/Eu3+. These results indicate
that HT/Tb3+ chelate was more sensitive than HT/Eu3+ chelate
whereas the Stokes shift of HT/Tb3+ was smaller than that of HT/Eu3+
(Supplementary Fig. S1).
Next, we compared HT/Tb3+ and HT/Eu3+ in tumor cell labeling
(Fig. 1). After human renal cell carcinoma cell lines 786-0, UOK111,
and UOK121 were treated with 25 μM BM-HT for 15min at 37 °C, the
spontaneous release and maximum release in 60min were determined.
The spontaneous release and maximum release from 786‐0 for HT/
Tb3+ were 323,616 ± 5722 and 3,017,735 ± 56,323; and those for
HT/Eu3+ were 58,981 ± 1113 and 504,034 ± 16,253, respectively.
Fig. 3. Vγ2Vδ2+ γδ T cell-mediated cytotoxicity against various tumor cell lines. The specific lysis by Vγ2Vδ2+ γδ T cells (HD04) of HT-labeled and PTA-sensitized
human tumor cell lines C1R, UOK111, K562, P31/FUJ, KG-1, and U937 were determined (○, 0 nM PTA; ●, 200 nM PTA). Data show mean ± SD and are re-
presentative of three independent experiments.
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Similarly, the spontaneous release and maximum release from UOK111
for HT/Tb3+ were 816,349 ± 16,390 and 4,193,751 ± 119,587;
those for HT/Eu3+ were 133,918 ± 3129 and 700,497 ± 121,991;
those from UOK121 for HT/Tb3+ were 210,204 ± 23,755 and
2,415,422 ± 155,314; and those for HT/Eu3+ were 42,388 ± 3098
and 457,706 ± 12,797, respectively. The spontaneous release rates (=
100 x spontaneous release/maximum release) of HT/Tb3+ and HT/
Eu3+ for 780-6 were 11% and 12%, those for UOK111 were 19% and
19%, and those for UOK121 were 9% and 9%, respectively. The results
indicated that the sensitivity of HT/Tb3+ was 5-fold to 6-fold higher
than that of HT/Eu3+, although the spontaneous release rate (%) was
essentially the same.
3.2. Comparison of Tb3+ and Eu3+ in cellular cytotoxicity assay
Next, we compared HT/Tb3+ and HT/Eu3+ in the determination of
the cellular cytotoxicity exhibited by Vγ2Vδ2+ γδ T cells. In order to
validate the non-radioactive cellular cytotoxicity assay system for the
measurement of tumoricidal activity exhibited by human Vγ2Vδ2+ γδ T
cells, peripheral blood samples were obtained from healthy adult vo-
lunteers and peripheral blood mononuclear cells (PBMCs) were pur-
ified. As previously described, tetrakis-pivaloyloxymethyl 2-(thiazole-2-
ylamino)ethylidene-1,1-bisphosphonate (PTA) was used for the ex-
pansion of Vγ2Vδ2+ γδ T cells (Matsumoto et al., 2016; Tanaka et al.,
2017; Tanaka et al., 2018). After stimulation of PBMCs with PTA and
IL-2 for 11 days, Vδ2+ cells occupied 98% or more of the lymphocyte
gate in three healthy adult PBMCs (HD01: 99.7%, HD02: 99.3% and
HD3: 98.4%).
PTA (0 nM or 200 nM)-sensitized 786-0 cells were then labeled with
BM-HT and challenged by PTA-expanded Vγ2Vδ2+ γδ T cells derived
from three healthy adult volunteers (HD01, HD02, and HD03). As
shown in Fig. 2, Vγ2Vδ2+ γδ T cells failed to kill 786-0 cells that had
not been sensitized by PTA whereas effector to target ratio–dependent
cytotoxicity was observed when 786-0 cells were pretreated with
200 nM PTA. It is of note that essentially the same specific lysis (%) was
obtained in HT/Tb3+ and HT/Eu3+detection systems for all three do-
nors.
Although the intensity of emission fluorescence from HT/Eu3+ was
weaker than that from HT/Tb3+, the intensity increased with the in-
creasing concentration of HT/Eu3+, as shown in Supplementary Fig. S2.
This demonstrates that the HT/Eu3+ assay system is as good as the HT/
Tb3+ assay system when the efficiency of tumor cell labeling is high.
3.3. Measurement of Vγ2Vδ2+ γδ T cell–mediated cytotoxicity against
tumor cells
It was previously demonstrated that lymphoma and myeloid leu-
kemia cells were poorly sensitized by zoledronic acid at sub-micromolar
concentrations. We therefore set out to determine Vγ2Vδ2+ γδ T
cell–mediated cytotoxicity against PTA (200 nM)–pretreated lymphoma
and myeloid leukemia cells using the non-radioactive BM-HT–based
assay system. Although the HT/Tb3+ assay system was more sensitive
Fig. 4. Vγ2Vδ2+ γδ T cell–mediated ADCC against
RAMOS-RAI. (A) Flow cytometric analysis of
Vγ2Vδ2+ γδ T cells. The expression of CD16 on PTA/
IL-2–expanded Vγ2Vδ2+ γδ T cells (HD05 and
HD06) were examined by flow cytometry (dotted
line: open area, isotype–matched control Ab; solid
line: filled area, anti-CD16 mAb). A representative
result of three independent experiments is shown.
(B) Determination of ADCC exhibited by Vγ2Vδ2+
γδ T cells against RAMOS-RAI. The effect of anti-
CD20 mAb (○, 0; ▲, 0.5; ●, 2 μg/mL) on the spe-
cific lysis by Vγ2Vδ2+ γδ T cells (HD05 and HD06)
of the HT-labeled RAMOS-RAI cell line. Data show
mean ± SD and are representative of three in-
dependent experiments.
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than the HT/Eu3+ system, lymphoma and myeloid leukemia cells were
efficiently labeled with BM-HT, and the HT/Eu3+ assay system was
thus employed to measure cytotoxicity for further study. In addition,
the TRF multiplate reader for the Eu3+ chelate is more common in
standard biomedical laboratories.
PTA (0 nM or 200 nM)-sensitized C1R B cell lymphoma cells were
labeled with BM-HT and challenged by Vγ2Vδ2+ γδ T cells derived
from a healthy adult volunteer (HD04). Although PTA–untreated C1R
cells were resistant to Vγ2Vδ2+ γδ T cells, PTA (200 nM)–sensitized
C1R cells were efficiently killed by Vγ2Vδ2+ γδ T cells in an effector to
target ratio–dependent manner (Fig. 3A, upper left panel). The specific
lysis against PTA–sensitized C1R was higher than that against PTA–-
sensitized UOK111 renal cell carcinoma cell lines (Fig. 3A, upper right
panel). Similarly, PTA (200 nM)–sensitized K562 erythrocytoma cells,
and P31/FUJ, KG-1, and U937 monocytic cell lines, were also effi-
ciently killed by Vγ2Vδ2+ γδ T cells in an effector to target ratio–de-
pendent manner (Fig. 3A, middle and lower panels). This demonstrates
that a newly developed BM-HT–based assay system can be used for the
determination of Vγ2Vδ2+ γδ T cell–mediated cellular cytotoxicity
against adherent and non-adherent tumor cells. Essentially the same
results were obtained in two other healthy donors, as shown in Sup-
plementary Figs. S3 and S4.
3.4. Measurement of Vγ2Vδ2+ γδ T cell–mediated antibody–dependent
cellular cytotoxicity
Next, we examined whether the assay system could be used for the
determination of Vγ2Vδ2+ γδ T cell–mediated antibody–dependent
cellular cytotoxicity (ADCC). Because ADCC is mediated by CD16, we
first screened several healthy adult volunteers for the expression of
CD16 on Vγ2Vδ2+ γδ T cells. As shown in Fig. 4A, Vγ2Vδ2+ γδ T cells
derived from a healthy adult volunteer (HD05) did not express CD16
whereas those from HD06 expressed a high level of CD16.
We thus compared ADCC between HD05 and HD06's Vγ2Vδ2+ γδ T
cells. RAMOS-RAI Burkitt's lymphoma cells were pretreated with 0, 0.5,
or 2 μg/mL of anti-CD20 mAbs and BM-HT for 15min at 37 °C and
challenged by Vγ2Vδ2+ γδ T cells derived from HD05 and HD06. As
shown in Fig. 4B, mAb–untreated RAMOS-RAI cells were not killed by
HD05 Vγ2Vδ2+ γδ T cells whereas CD16–expressing HD06 Vγ2Vδ2+ γδ
T cells exhibited ADCC in an mAb concentration–dependent manner.
Essentially the same result was obtained in another combination of
healthy donors, as shown in Supplementary Fig. S5. This observation
clearly demonstrated that the newly developed assay system using BM-
HT could be used for the measurement of Vγ2Vδ2+ γδ T cell–mediated
ADCC.
4. Discussion
Cell–mediated cytotoxicity is commonly determined using a
[51Cr]‑sodium chromate release assay in immunology laboratories
(Brunner et al., 1968). Although this radioactive assay system is re-
producible and reliable, it is challenging to use γ-rays in clinical la-
boratories for cancer cell therapies. A number of non-radioactive
methods have thus been developed to measure cellular cytotoxicity,
including the detection of enzyme activity and flow cytometry. The
[51Cr]‑sodium chromate release assay has not been replaced by these
alternatives that have a relatively low level of sensitivity and a poor
labeling of some target cells.
One of the most promising methods is the assay using TRF, in which
the target cells are pre-labeled with a chelate–forming non-radioactive
probe and the amount of intracellular and extracellular probes are
compared by mixing with Eu3+ after a challenge by immune effector
cells (Blomberg et al., 1996). For the labeling of tumor cells with
[51Cr]‑sodium chromate, the probe is passively internalized into tumor
cells and binds to intracellular proteins. The resulting probe/protein
complex is retained inside the cells, leading to a relatively slow
spontaneous rate. In the case of a non-radioactive chelate-forming
probe prodrug, the hydrophobic compound permeates target cells
where it is hydrolyzed to give a functional probe. Since the resulting
chelate–forming probe is negatively charged, it is retained in the cy-
toplasm for some time. It does not, however, interact with intracellular
proteins and is eventually released from the cells. Thus, the sponta-
neous release rate of non-radioactive probes is generally greater than
that of [51Cr]‑sodium chromate.
We previously synthesized BM-HT that was improved in the in-
tracellular retention and labeling efficiency, compared to conventional
bis(acetoxymethyl)2.2′:6′,2″-terpyridine-6.6″-dicarboxylate (BATDA)
(Blomberg et al., 1996). We demonstrated that BM-HT could be used as
a probe for the measurement of NK cell–mediated cytotoxicity (Senju
et al., 2018). It is known that innate immune cells like NK cells can kill
tumor cells and virus–infected cells rapidly. NK cells have been called
large granular lymphocytes because they have a large amount of in-
tracellular granules containing perforin and granzyme B that are re-
sponsible for cellular cytotoxicity. In contrast, adaptive immune cells
like CD8+ αβ T cells kill target cells rather slowly as they have to be
primed and activated before killing. γδ T cells are considered to be
immune cells that have properties of both innate and adaptive immune
cells since they express rearranged TCRs and kill tumor cells and virus-
infected cells rapidly (Constant et al., 1994; Tanaka et al., 1994; Tanaka
et al., 1995; Hintz et al., 2001; Rohdich et al., 2002; Harly et al., 2012;
Wang et al., 2013). We thus examined whether or not the specific lysis
of tumor cells by γδ T cells could be determined with the improved
assay system using BM-HT.
We first attempted to increase the sensitivity of the non-radioactive
cellular cytotoxicity assay using BM-HT. To detect chelate-forming
probes, Eu3+ has often been used as a chelate partner, and the probe/
Eu3+ chelate has a relatively large Stokes shift. When the Stokes shift is
large, the difference between the excitation wavelength and the emis-
sion wavelength is large, and the superimposition of the excitation
pulse onto the emission fluorescence is limited. Compared to Eu3+
chelate, Tb3+ chelate has a rather small Stokes shift upon excitation
with 340 nm pulse. The fluorescence intensity of HT/Tb3+ chelate is,
however, 5- to 6-fold stronger than that of HT/Eu3+ chelate, and no
emission interference due to the excitation pulse is noted. This indicates
that the assay system using HT/Tb3+ is more sensitive than that using
HT/Eu3+.
Even though the sensitivity of HT/Tb3+ chelate is higher than that
of HT/Eu3+ chelate, the availability of the TRF multiplate reader for
Tb3+ chelate is limited in biomedical laboratories compared to that for
Eu3+ chelate. We thus examined the HT/Eu3+ dose–dependency for
emission fluorescence intensity. When the dose of HT/Eu3+ chelate was
increased, the emission intensity reached the level of HT/Tb3+ chelate,
indicating that the system using a high concentration of HT/Eu3+ is as
sensitive as that using HT/Tb3+ chelate. Next, we sought to identify
tumor cell lines that could be labeled with BM-HT efficiently, since such
lines produce a high concentration of intracellular HT. As demonstrated
in this study, lymphoma and myeloid leukemia cells could be efficiently
labeled with BM-HT. We then examined Vγ2Vδ2+ γδ T cell–mediated
cytotoxicity against lymphoma and myeloid leukemia cells. As ex-
pected, the tumoricidal activity of Vγ2Vδ2+ γδ T cells against
PTA–treated and anti-CD16 mAb–treated tumor cells could be suc-
cessfully measured. In the future, we plan to synthesize a different
series of prodrugs of chelate-forming probes that could be used to de-
termine αβ T cell–mediated cytotoxicity.
Recently, significant attention has been focused on combination
therapies using programmed death-1 (PD-1) immune checkpoint in-
hibitors and other therapeutics (Forde et al., 2018; Gandhi et al., 2018;
Hellmann et al., 2018), because the efficacy of PD-1 immune check-
point monotherapy is limited (Motzer et al., 2015; Weber et al., 2017).
One of the most attractive combination partners are ex vivo–expanded
immune effector cells, including NK cells, Vγ2Vδ2+ γδ T cells, and
genetically–modified T cells (Hiasa et al., 2009). The measurement of
M.S.O. Tagod et al. Journal of Immunological Methods 466 (2019) 32–40
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cellular cytotoxicity is critical, and the non-radioactive assay estab-
lished in this study is expected to play an important role in the devel-
opment of such combination therapies.
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